课题基金 / 基金详情

US-China Collaborative Research on Stroke Imaging

US-China Collaborative Research on Stroke Imaging
中美脑卒中影像学合作研究
批准号:
8879226
负责人:
JINYUAN ZHOU
金额:
$19.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-01 至 2017-07-31

项目摘要

项目成果

JINYUAN ZHOU的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):约翰霍普金斯大学和北京医院的研究人员合作的这个项目的总体目标是验证一种新的综合MRI检查方案,包括pH、扩散和灌注成像,用于评估缺血性卒中和卒中康复。中风是全球成年人死亡和残疾的主要原因,在中国和美国分别位居第二和第四。目前,FDA批准的唯一治疗缺血性中风的药物是静脉注射组织型纤溶酶原激活剂(IV TPA),该药物在症状出现后三个小时内给予。中风发作后出现超过三个小时的患者现在只在几个临床试验中接受治疗。然而,对于这类疗法的选择标准仍然没有很好的定义。不幸的是,接受tPA治疗的患者出血风险增加,这一事实使情况进一步复杂化。因此,应根据缺血半暗带的存在和范围,对tPA的益处和风险进行个体评估,缺血半暗带的定义是仍可存活但有梗死风险的组织。APT成像是一种全新的磁共振成像方法,可以无创地检测组织的pH值。这种完全无创的pH成像方法可以识别有氧代谢受损后组织酸中毒的区域。我们假设,由于组织酸中毒导致的卒中pH加权成像(PHWI)缺陷,可以预测如果没有开始再灌注,最终的最大梗塞范围,并且在灌注/扩散MRI方案中加入APT-pH成像可以更好地显示缺血半暗带,从而改善对最终梗塞范围和结果的预测。我们将在动物身上测试我们的假设,使用临床相关的大脑中动脉阻塞模型,并对超急性和急性缺血性中风患者进行试点人体扫描,以评估这项新技术在临床上的可能应用。我们的具体目标是:(I)评估大鼠脑缺血/再灌注模型中灌注/pH/扩散缺陷的特征和时空演变;(Ii)确定超急性和急性缺血性卒中患者的放射学特征和临床价值。如果假设被证明是正确的,我们希望有一个额外的标记物,可以在临床上用于中风患者的诊断和预后。
英文摘要
DESCRIPTION (provided by applicant): The overall goal of this collaborative research project between researchers at Johns Hopkins University and Beijing Hospital is to validate a novel comprehensive MRI exam protocol, including pH, diffusion, and perfusion imaging, for the assessment of ischemic stroke and recovery from stroke. Stroke is a leading cause of death and disability among adults worldwide, second in China and fourth in the US. Currently, the only FDA- approved treatment for ischemic stroke is intravenous tissue plasminogen activator (IV tPA) that is given within three hours of symptom onset. Patients who present beyond three hours after stroke onset are now treated in several clinical trials only. However, the selection criteria for this type of therapy are still not well defined. This is further complicated by the unfortunate fact that patients who receive tPA are at increased risk for hemorrhage. Thus, the benefit versus risk with tPA should be assessed on an individual basis, based on the presence and extent of an ischemic penumbra, defined as tissue that is still viable but at risk of infarctio. APT imaging is an entirely new MRI methodology that can non-invasively detect tissue pH. This totally noninvasive pH imaging method can identify regions of tissue acidosis following impaired aerobic metabolism. We hypothesize that the pH-weighted imaging (pHWI) deficit in stroke, due to tissue acidosis, predicts the maximum final infarction size if no reperfusion is initiated, and he addition of APT-pH imaging to the perfusion/diffusion MRI protocol could better visualize an ischemic penumbra, thus improving predictions about final infarct size and outcome. We will test our hypothesis on animals, using a clinically relevant middle cerebral artery occlusion model, and perform pilot human scanning on hyperacute and acute ischemic stroke patients to assess the possible utility of this new technique in the clinic. Our specific aims are: (i) to assess the characteristics and spatio-temporal evolution of perfusion/pH/diffusion deficits in rat brain ischemia/reperfusion models; and (ii) to determine the radiologic characteristics and clinical values of pH imaging of hyperacute and acute ischemic stroke patients. If the hypotheses are proven correct, we expect to have an additional marker that can be used for diagnosis and prognosis of stroke patients in the clinic.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Developing Protein-based MRI Biomarkers for Alzheimer's Disease
  • 批准号:
    10260539
  • 项目类别:
  • 资助金额:
    $66.43万
  • 财政年份:
    2020
  • 负责人:
    JINYUAN ZHOU
  • 依托单位:
Developing Protein-based MRI Biomarkers for Alzheimer's Disease
  • 批准号:
    10636831
  • 项目类别:
  • 资助金额:
    $64.64万
  • 财政年份:
    2020
  • 负责人:
    JINYUAN ZHOU
  • 依托单位:
Developing Protein-based MRI Biomarkers for Alzheimer's Disease
  • 批准号:
    10053946
  • 项目类别:
  • 资助金额:
    $66.23万
  • 财政年份:
    2020
  • 负责人:
    JINYUAN ZHOU
  • 依托单位:
Developing Protein-based MRI Biomarkers for Alzheimer's Disease
  • 批准号:
    10403604
  • 项目类别:
  • 资助金额:
    $69.11万
  • 财政年份:
    2020
  • 负责人:
    JINYUAN ZHOU
  • 依托单位:
海外基金